Medicare will cover Alzheimer’s disease drugs granted traditional FDA approval, CMS announced. But the decision keeps the spirit of an earlier coverage determination, which called for the gathering of more evidence about the safety and efficacy of these therapies.
Operator: Hello and welcome to the Axsome Therapeutics First Quarter 2023 Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Biogen Inc said on Tuesday it will pause or discontinue at least four studies of experimental drugs to focus on more potentially lucrative options including its second Alzheimer s treatment, Leqembi,
Karuna Therapeutics has licensed two small molecules that shuttering Goldfinch Bio had developed for kidney disorders. These compounds target a pathway that could also treat neurological disorders, giving clinical-stage Karuna the opportunity to compete against a drug candidate from Boehringer Ingelheim.
Eisai Alzheimer’s disease drug Leqembi is now approved for the treatment of patients with an early form of the memory-robbing disease. In granting the antibody accelerated approval, the FDA employed reasoning that was the also basis for the controversial speedy regulatory nod for Biogen’s drug, Aduhelm.
Japanese drugmaker Eisai Co Ltd said on Friday it had priced its newly approved Alzheimer s disease drug called Leqembi at $26,500 a year.Eisai developed the drug with Biogen Inc.Wall Street analysts were expecting the drug to be priced at roughly $20,000
Operator: Good afternoon and welcome to the Aptinyx Third Quarter 2022 Financial Results Conference Call. At this time, all participants are on listen-only mode.